<DOC>
	<DOC>NCT02923206</DOC>
	<brief_summary>This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb sFlt-1 adsorber treatment of pregnant patients with preeclampsia.</brief_summary>
	<brief_title>Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis</brief_title>
	<detailed_description />
	<mesh_term>Pre-Eclampsia</mesh_term>
	<criteria>Reduced criteria! Phase 0 Age ≥18 and ≤45 years; Male or female; Female subjects of childbearing potential must have a negative serum pregnancy test result at screening and practice two reliable methods of contraception throughout the study. Dysfunction of cerebral nervous system and/or heart disease; History of preexisting chronic renal disease; Treatment with ACE inhibitors; Therapeutic full anticoagulation therapy prior to trial entry; Liver abnormalities; Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia; Active hepatitis B, C, or tuberculosis infection or HIV infection Hypersensitivity to heparin and/or citrate; Indications that prohibit transient anticoagulation using heparin and/or ACDAsolutions; Known intolerance to extracorporeal procedures in general or towards one of the individual excipients or towards other supporting agents; Drug or alcohol abuse within the last 2 years; Lack of compliance of subject; History or diagnosis of severe periodontitis; Phase A and B Age &gt;18 and ≤45 years ; Pregnant woman with preterm preeclampsia sFlt1/PlGF ratio ≥85 ; sFlt1 level of ≥ 8000pg/mL Maternal exclusion criteria History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease; History of preexisting chronic renal disease and/ or preexisting clinically significant proteinuria, prior to pregnancy; Treatment with ACE inhibitors/ reninangiotensinsystem blocker; Therapeutic full anticoagulation therapy prior to trial entry; Signs or history of clinically significant cerebral nervous system dysfunction; History of clinically significant liver abnormalities; Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia; Active hepatitis B, C, tuberculosis infection or HIV infection; Any condition that the investigator deems a risk to the patient or fetus in completing the trial; Indications that prohibit transient anticoagulation using heparin and/or ACDAsolutions; Drug or alcohol abuse within the last 2 years; Lack of compliance of patient; Known intolerance to extracorporeal procedures in general or to one of the excipients or other supporting agents; Hypersensitivity to heparin and/or citrate; Evidence of "reverse or zero Doppler" flow on umbilical Doppler; Various Placental exclusion criteria; Multiple pregnancy History or diagnosis of severe periodontitis Various fetal exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>apheresis</keyword>
	<keyword>pregnancy</keyword>
	<keyword>pre-eclampsia</keyword>
	<keyword>PE</keyword>
	<keyword>sFlt-1</keyword>
	<keyword>Pre-term</keyword>
</DOC>